wild-type interleukin-12 T cells

Wild-type interleukin-12 T cells (wtIL12-T) are genetically engineered T cells designed to constitutively express and secrete native, soluble interleukin-12 (IL-12). In the context of cancer immunotherapy research, these cells serve as a benchmark for "armored" T-cell therapies. IL-12 is a potent pro-inflammatory cytokine that activates T cells and natural killer (NK) cells and induces the production of interferon-gamma (IFNγ). Unlike newer generations of armored T cells that anchor IL-12 to the cell membrane (e.g., attIL12), wtIL12-T cells release high levels of soluble IL-12 into the systemic circulation. While this approach demonstrates significant antitumor efficacy in preclinical models of osteosarcoma and melanoma, it is associated with severe off-tumor toxicities, including hepatitis and systemic cytokine release syndrome, which has limited its clinical application.

Other names

wtIL12-transduced T cellswtIL-12-transduced T cellswtIL 12-transduced T cellswild-type IL-12 armored T cells